Collaborative study finds kānuka oil product effective for eczema.
The first clinical trial investigating the use of kānuka oil for eczema relief has shown that it is an effective emollient (a product that soothes and protects the skin) for treating moderate-to-severe eczema in adults, with results being published in the prestigious Lancet Group’s eClinicalMedicine Journal.
This landmark trial was conducted by the MRINZ in partnership with Hikurangi Bioactives Limited Partnership (HBLP) and TRG Natural Pharmaceuticals. HBLP is a social enterprise committed to creating jobs and economic development for Māori communities in the Tairāwhiti region; and Tauranga-based TRG Natural Pharmaceuticals develops innovative and scientifically proven natural products.
Lead study author and MRINZ PhD student, Nick Shortt says:
“It’s brilliant to be working closely with New Zealand biotechnology companies committed to undertaking research on the efficacy and safety of the natural health products they’re developing. Emollients are often the first step in managing eczema symptoms, reducing the frequency of flare ups and the need for topical steroids. By adding 3% kānuka oil to emollient cream, we’ve shown a significant reduction in eczema symptoms.”
Eczema is a chronic condition that damages the skin barrier function, causing skin to become dry, red, itchy and prone to infection. If left untreated, it can significantly affect sleep patterns and impact everyday activities.
Affecting one in three New Zealanders at some stage throughout their lives, eczema is common among young New Zealanders—especially young Māori and Pacific peoples.
The study gathered data from 80 individuals across the country, with 25% of which being Māori—higher than both of the most recent census population estimates of 16.5% and previous participation rates in eczema studies undertaken in Aotearoa New Zealand.
Conducted through the MRINZ’s Pharmacy Research Network, the trial investigated the efficacy and safety of a 3% kānuka oil cream compared to a control cream. Founded and managed by the MRINZ, in partnership with the New Zealand Pharmacy Guild, the PRN is composed of research-trained pharmacies across the motu.
Adjunct Professor Alex Semprini, MRINZ Deputy Director and PRN programme lead, says:
“The Pharmacy Research Network is a socially driven and evidence-based long-term research partnership—helping to inform patients of their therapeutic choices and enhancing community pharmacy-led services. The PRN framework was crucial in allowing us to complete this trial despite the impediments that a global pandemic put in the way of medical research.”
Endemic to Aotearoa New Zealand, kānuka is a part of Rongoā Māori, possessing anti-inflammatory and anti-bacterial properties to treat conditions such as urinary infections, colds, back pain, burns, and various skin conditions.
After participants applied the kānuka treatment twice daily over six weeks, the study found that eczema symptoms in those who had been using the kānuka oil cream improved more than those in the control group.
With such strong trial results, TRG Natural Pharmaceuticals and HBLP are in early conversations with local distributors and are looking to market the formula internationally.
HBLP Co-Founder Manu Caddie, says:
“The success of this trial is hugely exciting and could lead to a sustainable and profitable industry for the Tairāwhiti region, providing new jobs for local people. The experience has been invaluable and is leading us to many other opportunities to prove the safety and efficacy of products derived from compounds found in other natural sources.”
